The cancer diagnostics company has gone into a trading halt following an adverse decision on reimbursement of its US bladder tests.
Board and management ‘accept and apologise for these long standing failings’, chair Julian Cook says.
Full-year results out this morning show company’s hopes are pinned on approval – but it has some backup plans.
Net profit declined 95% to $24 million in the year ended March 31, following asset sale the previous year.
But CEO Gary Miles warns against extrapolating current ‘rest of world’ segment growth to core NZ/Aus/UK markets.
Aucklanders can count on higher public transport tariffs and congestion charging, though tapping into Govt coffers could prove a speed bump.
New Zealand proves to be the jewellery brand's most challenged market.
The dual-listed software company's stock value has more-than quadrupled since late 2022.
Listed honey company has reduced 2024 earnings guidance and says 2025 target very unlikely to be met.
Regulators have been coming down hard on casino operators and their breaches of anti-money laundering and counter-terrorism financing legislation.